Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance. The company applies insights into genetic mutations to develop a pipeline addressing prevalent psychiatric and neurologic conditions and rare diseases. Praxis has established a portfolio that includes five disclosed programs across depression, epilepsy, movement disorders and pain syndromes. Three programs are currently in clinical development for five indications: PRAX-114 (Phase 2 for major depressive disorder and perimenopausal depression), PRAX-944 (Phase 2 for essential tremor), and PRAX-562 (Phase 1 for pediatric epilepsy and adult cephalgia). The company also has additional programs in earlier stages of development. Recently announced financing is intended to support continued advancement of its clinical pipeline. Praxis Precision Medicines, based in Cambridge, Mass., launched with more than $100 million in financing since its inception. The company applies a precision medicine approach using genetic insights to develop therapies that target underlying causal mechanisms across neuropsychiatric, movement and rare epilepsy disorders. Its lead programs are PRAX-114, a GABAA positive allosteric modulator in Phase 2 for major depressive disorder and perimenopausal depression, and PRAX-944, a T-type calcium channel blocker in Phase 2 for essential tremor. Within the next year Praxis plans to initiate a first pivotal trial for PRAX-114, report proof-of-concept data for PRAX-944, and advance earlier-stage programs into clinical development for rare epilepsies and other genetically validated CNS disorders. The company emphasizes leveraging recent genetic discoveries in epilepsy and related biology to develop targeted CNS therapies. The launch and stated plans are positioned around advancing these clinical-stage programs toward pivotal and proof-of-concept milestones.

Total raised

$210M

Funding rounds

2

Latest round

Series C

Latest activity

Jul 2020